Angina Pectoris Drugs Market Size, Share, Trends, Growth Outlook

Angina Pectoris Drugs Market is estimated to increase at a growth rate of 6.1% CAGR over the forecast period from 2024 to 2030.

The Angina Pectoris Drugs Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Therapeutic Class (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors), Anti-Platelets, Others).

An Introduction to Angina Pectoris Drugs Market in 2024

The Angina Pectoris Drugs Market in 2024 is experiencing notable growth, driven by the increasing prevalence of coronary artery disease, growing demand for anti-anginal medications, and advancements in cardiovascular pharmacotherapy to improve angina symptoms and reduce cardiovascular events. Angina pectoris, characterized by chest pain or discomfort due to reduced blood flow to the heart muscle, represents a significant clinical challenge and a leading cause of morbidity and mortality worldwide. With advancements in drug development, personalized medicine approaches, and interventional cardiology techniques, the market offers a variety of angina pectoris drugs, including anti-anginal agents (e.g., beta-blockers, calcium channel blockers, nitrates), antiplatelet therapies, and lipid-lowering medications, aimed at improving myocardial oxygen supply-demand balance and preventing ischemic events. Moreover, emerging therapies targeting novel pathways, such as anti-inflammatory agents and endothelial function modulators, hold promise for further optimizing angina management and improving long-term outcomes for patients with coronary artery disease.

Angina Pectoris Drugs Market Trend: Increasing Adoption of Combination Therapies

A prominent trend in the Angina Pectoris Drugs market is the growing adoption of combination therapies for the management of angina symptoms. Physicians are increasingly prescribing combination drug regimens that target multiple pathways involved in angina pathophysiology, such as antiplatelet agents, beta-blockers, calcium channel blockers, nitrates, and statins. This approach aims to provide comprehensive symptom relief, improve exercise tolerance, and reduce the risk of cardiovascular events by addressing various underlying mechanisms contributing to angina.

Angina Pectoris Drugs Market Driver: Rising Prevalence of Cardiovascular Diseases

A key driver propelling the Angina Pectoris Drugs market is the escalating prevalence of cardiovascular diseases, including coronary artery disease (CAD) and associated conditions such as hypertension, dyslipidemia, and diabetes mellitus. Angina pectoris, a common manifestation of CAD, affects millions of individuals worldwide and significantly impacts their quality of life. With the growing burden of cardiovascular risk factors due to sedentary lifestyles, unhealthy dietary habits, and aging populations, there is a continuous demand for pharmacological interventions to manage angina symptoms and prevent cardiovascular events, driving market growth.

Angina Pectoris Drugs Market Opportunity: Development of Novel Anti-Anginal Agents

An opportunity in the Angina Pectoris Drugs market lies in the development of novel anti-anginal agents with innovative mechanisms of action and improved efficacy and safety profiles. Despite the availability of various pharmacological treatments for angina, there remains a need for therapies that offer enhanced symptom relief, reduced side effects, and better tolerability. Pharmaceutical companies investing in research and development can explore novel drug targets, such as myocardial oxygen demand reduction, coronary vasodilation, and endothelial function modulation, to develop next-generation anti-anginal medications. By addressing unmet needs in angina management, these innovative therapies have the potential to capture market share and drive revenue growth in the Angina Pectoris Drugs market.

Angina Pectoris Drugs Market Segmentation

By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Angina Pectoris Drugs Market Companies

Amgen Inc
AstraZeneca Plc
Eli Lilly and Company
Gilead Sciences Inc
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc
Sanofi S.A.
Tasly Pharmaceuticals Inc
XyloCor Therapeutics Inc

 

 

Reasons to Buy the Angina Pectoris Drugs Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Angina Pectoris Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Angina Pectoris Drugs Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Angina Pectoris Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Angina Pectoris Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Angina Pectoris Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Angina Pectoris Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Angina Pectoris Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Angina Pectoris Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Angina Pectoris Drugs Market Industry
4.2 Key Market Trends in Angina Pectoris Drugs Market Industry
4.3 Potential Opportunities in Angina Pectoris Drugs Market Industry
4.4 Key Challenges in Angina Pectoris Drugs Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Angina Pectoris Drugs Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Angina Pectoris Drugs Market Outlook By Segments
7.1 Angina Pectoris Drugs Market Outlook by Segments
By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others

8 North America Angina Pectoris Drugs Market Analysis And Outlook To 2030
8.1 Introduction to North America Angina Pectoris Drugs Markets in 2024
8.2 North America Angina Pectoris Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Angina Pectoris Drugs Market size Outlook by Segments, 2021-2030
By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others

9 Europe Angina Pectoris Drugs Market Analysis And Outlook To 2030
9.1 Introduction to Europe Angina Pectoris Drugs Markets in 2024
9.2 Europe Angina Pectoris Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Angina Pectoris Drugs Market Size Outlook By Segments, 2021-2030
By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others

10 Asia Pacific Angina Pectoris Drugs Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Angina Pectoris Drugs Markets in 2024
10.2 Asia Pacific Angina Pectoris Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Angina Pectoris Drugs Market size Outlook by Segments, 2021-2030
By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others

11 South America Angina Pectoris Drugs Market Analysis And Outlook To 2030
11.1 Introduction to South America Angina Pectoris Drugs Markets in 2024
11.2 South America Angina Pectoris Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Angina Pectoris Drugs Market size Outlook by Segments, 2021-2030
By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others

12 Middle East And Africa Angina Pectoris Drugs Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Angina Pectoris Drugs Markets in 2024
12.2 Middle East and Africa Angina Pectoris Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Angina Pectoris Drugs Market size Outlook by Segments, 2021-2030
By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Amgen Inc
AstraZeneca Plc
Eli Lilly and Company
Gilead Sciences Inc
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc
Sanofi S.A.
Tasly Pharmaceuticals Inc
XyloCor Therapeutics Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others